these are sandra's "homemade" yummy, scrumptious bars. hmm? i just wanted you to eat more fiber. chewy, oatie, gooeyness... and fraudulence. i'm in deep, babe. you certainly are. [ male announcer ] fiber one. my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. hey, i'm cramer! welcome to "mad money." welcome to cramerica. other people want to make friends. i'm just trying make you a little money. my job is not just to entertain you but to educate you, too. call me at 1-800-743-cnbc. unless you're a bowler, you have no idea what the heck it means when i say this market has got

some of the best pin action i have ever seen. i can't take you to the lanes, i can't form a league with you, i can't even share my psychedelically laced bowling shoes with you. given today's action, the s&p jumping 1.25%, nasdaq vaulting 1.36%. by golly, i'm going to get you a shirt, a ball and a couple of lanes. this market is rolling strikes. the head pin smashes into the king pin and sends the rest shattering. today we had more pin action than the plaza lanes in madison,

new jersey, and i felt like it was like the old days when i donned my jim bowling shirt, put on shoes, brought my own ball and played with style. let's go over some of the strikes this market rolled because this one felt pretty darn perfect from start to finish. no, check that, from before the start to the finish. much of the positive pin action started overseas the night before where we've become so used to getting bad news. that's right. before we even opened for trading, you knew it was going to be a good one because of the pin action from the number, 50.3. that's the number china's industrial pmi or its gauge of strength hit last night and the number the eurozone came out with. yup, an odd coincidence. but remember, 50 is the fulcrum. anything north of fifty is expansion. given that we expected contractions with both numbers,

the gains, they were instantaneous. for months the worst performing stocks have been the big mining metals because china is knee deep in all of those things. and you know what? for a while they were running lean but they don't need any of this stuff. in fact, the smart money, the hedge fund managers have been knocking and shorting everything that can possibly be used to build anything in china. that's been going on for months now. don't get me wrong, it has been a terrific trade. but when you get any number, but particularly this number out of china last night, get out of the way because the pin action, it is phenomenal! caterpillar has been among the worst performing stocks in the dow.

the manager came to cnbc's delivering alpha conference and said his favorite was caterpillar because they placed such a big bet on china and had come up snake eyes. he stressed the super cycle, the big commodity super cycle, they were kaput. secular decline. curse words when it comes to stocks. i have to tell you, i'm not disagreeing with him. i think these mineral plays peaked in 2008 when china was still smoking. doesn't make much sense at all now and they've been the bane of my existence when it comes to charitable trust. i think cat makes the best machines but sadly cat not executing. however, today for once if you owned those stocks, you didn't roll a gutter ball. in fact, caterpillar led the group along with cummins. so many bowlers were caught leaning the wrong way, short selling bowlers, they might as well have been knocking back some long necks in the bar

behind the lanes. i think i saw the bears roll the balls over the gutter into the next aisle! funny guys. europe has been such a disappointment. you buy everything from the european banks to the american-based companies like the autos. globals pulls up more than the minerals, gets the oils to roll strike after strike. how about the fact that exxon, the biggest of the oils, reported a terrible number, yet the whole group save exxon and another terrible reporter, royal dutch soared in fabulous fashion. what kind of day was today?

in news stemming from the old fashioned permian basin, any oil with permian construction, even lowly worm chesapeake reported a good number, a strike right down the middle for once. and the stock closed at 24.95. if you want to see a bowler's paradise, a perfect game, look at the weekly unemployment claims roll, the strongest number since 2008. given that the fed said it's on hold just the other day, this number was perfect, gave you confidence the economy was indeed getting stronger, which means earnings could be stronger than what we're seeing. and we got our own pmi and it was much better than expected. when the economy is humming, what flies? the transports go flying. they're knocking down pins left and right. the market had been pretty darn doggy of late, not confirming so to speak.

the action in the rails, which had been stalled because of disappointing earnings from the big coal transporter was heartening for us commerce loving rail people. when jobless claims come down, spending goes higher. one of the most amazing first days we've had in ages. sprouts farmers market priced at 18, opened at 35 and rallied further to 40, more than doubling right off the bat, what a command performance, one that stole the show from whole foods. low claims means fewer loan losses for the banks and that group rolled its best game in months and it looks like jp morgan is breaking out to much higher levels. pity those who sold it when they had that whale problem. if you wanted to see pin action, look no further than the social, mobile and cloud space --

♪ hallelujah -- after yelp shot the lights out. yelp may be the new key to this market. and facebook tried to mount that dastardly 38 level. facebook continued its relentless drive toward its all-time high, stopping just $2 short of that goal. anything that even looked like yelp bolted higher today. how about a couple sites helping you find your dream home, trulia, zillow. marketo, finished up 1.58 and

after the bell linkedin, the social networking website packed on another ten after reporting a magnificent quarter. the action was breathtaking. along with so many different lanes that swept up all kinds of companies, including some that were expected to be disappointing. remember federal express, amazon, netflix increased, not just because "breaking bad" is going to start august 11th. got to fill yourself in. it was one remarkable session. it reminded us once more that the brilliant minds who say you can't buy stocks until you see real revenue growth, and preach endless caution as they talk about tapering. pessimists keep getting blindsided, the bears smacked by stampeding bulls. the bottom line, this month of august started off just like the last month finished, just remarkable, with a roar. it's as if the whole lane bowled above its head where nine was an embarrassment and a spare wasn't much better.

it was a confirmation once again those who believe things are better -- like i say, they're rolling 300, and those who think things are worse, gutter over and over again. the only answer for those of us parents out there is to bring the bumpers normally reserved for the eight and under crowd to the bears' den because they can't play to save their lives. nate in california, please. nate. >> caller: jim, nate bringing you a big california booyah. >> what's shaking, partner! >> caller: visa is what's shaking. we got durbin amendment, lawsuits, all that good stuff. i want to hear from the man is it speculative or is it warranted? >> the money is all going to mastercard.

visa spent some time in the wilderness. it's now ready to roar again. i think visa had a good quarter and is well managed. i like visa. tim in california, please. >> caller: tim here, wondering about taser. they reported upbeat yesterday. >> we're in a market where really great companies that report good numbers, i'm talking about the 3m ilk, they go higher. the tasers, too speculative for this guy. august came in like a lion, the market roars on and the pin action gets downright amazing! stay with cramer! coming up, earnings avalanche. the season's in high gear and tonight cramer's got a triple shot of ceo exclusives to keep you ahead of the game. first up, botox maker allergan stock is flat for the year while the rest of the market has been soaring.

will that frown soon be turned upside down and give you an injection of profits? and cloud marketing play marketo catapulted higher yesterday on a strong quarter. have you missed the rise or is now the time to get in? plus, it was once thought impossible in the medical industry, but could it work miracles on your portfolio? and later, need some yelp? it's the holy trinity, cloud, mobile and social. yelp's got it. shares are flying, but cramer's full review includes something you won't expect, all coming up on "mad money." don't miss a second of "mad money." follow @jimcramer on twitter, have a question? tweet jim, #madtweets. send jim an e-mail or give us a

call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com.

is allergan finally ready to rebound? we've liked the stock for a long time here on "mad money." but the last time allergan reported, the company announced a key product in its pipeline for macular degeneration needed additional work that would delay the drug's potential approval. the stock got slammed. then in june we learned that allergan's second biggest drug for dry eye might face generic competition sooner than expected. the stock dipped down. today it inched up slightly, after reporting a better than expected quarter. it delivered a 2 cent earnings beat and revenues exceeded expectations. it was clear many questions remain. has allergan gotten its groove back? let's find out with david pyott,

the chairman of allergan. welcome back to "mad money." >> thanks for having me back, jim. let's start with the company's performance. it's performing really well right now. we had good top line growth, over 10%. on a non-gaap earnings per share basis, we have about 16% in the second quarter, year to date 17%. so everything's looking good. we exceeded guidance expected by wall street on almost every front. our markets are growing, and we had eight fda approvals since 2010 and about four more approvals on the horizon for the next year or so. short term, things look great. >> you said in the conference call we've got some challenges. one of these challenges is the drug restasis, that you may have

some generic challenges. tell our viewers what you have in mind if things don't go allergan's way. >> absolutely. so let's first of all ground ourselves. restasis is the only approved drug in the united states for therapeutic dry eye, headed pretty rapidly towards $1 billion in sales, which makes it the largest non-retina drug in the market. we were somewhat surprised that fda put out guidance for public comment on a potential generic pathway. very unusual. they asked for comment upon doing effectively in test tube assays instead of doing patient clinical trials. fda to our knowledge has never approved a so-called emulsion eye drop in its history. an emulsion is a mixture of oil

and water and we all learned in school that's very complicated to suspend such a product in a bottle, let alone what happens in your eye. we will be submitting our comments. of course in doing all this, one has to keep patient safety very much in mind, because it will be terrible if a patient were to lose their vision or let alone completely their sight. >> what's interesting is that i think you've always been straight with us, straight with everybody and yet these analysts on the conference call, and the stock reflects the fact that people feel you can't stop this, that it is going to happen no matter what. what you just described will be a reason why the fda would be foolish to go right into a generic version. >> of course we've dealt historically with the scientists, these are the people who approve the drugs. you may remember long ago we had

our own challenges getting restasis approved some ten years ago. no other product ever approved since then. so now of course we have to work with the generics division, who have a different mission. their job is to reduce the cost of public health care, which we understand. many of our drugs have been genericized in the past appropriately and now we have to say to the generics division, maybe you have to be careful here. taking shortcuts could be quite dangerous. >> in the regeneron challenger, a lot of people were upset your stock was in the high hundreds, 110. you now said there was a delay. it now seems like you're now ahead of where we first thought you would be when you first announced that delay. am i reading that correctly, that maybe you're closer to having a product than two quarters ago? it could be something that's better than we think? >> obviously that's our job. so really my job is with our

scientists, is to show that darpin is delayed and very much not dead. most people thought it could be approved on the market by 2017. basically we said this could be fractionally delayed, up to 2018, 2019. and since three months ago we lost no time. we're already recruiting patients into the next trial. now, what have we changed? the first time around it would be quite unethical to force physicians to keep patients in the trial for a long time if they weren't convinced about either the safety or more significantly the efficacy of the drug. having had the readout from that last trial, we've now designed this current one where we're going to get a much better readout on duration.

excellent product, and they have picked up steam so fast on the original incumbent based on similar efficacy but slightly longer duration. if we can do that again, we have an absolutely gigantic product on our hands. just to put it in context, the world's retina market today is about $5 billion and growing in excess of 20% per year. >> i think you've answered both those. i want to circle back to the drug that seems to be doing fabulously. all the botox indications you've talked about are above planned from when you were on last. is that true? >> botox is performing very well. and of course this is a product with enormous carry because we are creating new market segments, chronic migraine, bladder indications, upper limb spasticity. i'm always a little bit delayed because i have to look at the

market data and competitor information. the world market grew 15% year over year and we grew 16%. so we actually gained share across the board. that's amazing when you think botox, with all of its competition around the world, we're very close to 80% of the world market in value. >> okay, david. thank you. you've been, again, always straightforward. the challenges are there. i think the opportunities are not in the stock. i want to thank you so much for coming on, david pyott, chairman and ceo of allergan. >> the stock reflects neither this new macular degeneration drug that is ahead of plan nor the genetic challenger. i'm with him. stay with cramer. >> coming up, need some yelp? it's the holy trinity, cloud, mobile and social, and yelp's got it. after beating the street, shares are flying. but cramer's full review includes something you won't

expect. don't miss it next. so... [ gasps ]

these are sandra's "homemade" yummy, scrumptious bars. hmm? i just wanted you to eat more fiber. chewy, oatie, gooeyness... and fraudulence. i'm in deep, babe. you certainly are. [ male announcer ] fiber one. who has mastered mobile? who can make money in mobile advertising and not be crushed by the cheaper modernized

ad programs? facebook, and now as of last night we discovered that yelp can do. yelp is thriving with second quarter sales up 69% on special initiatives that actually make mobile better than any other what device for the review and spend site. review and spend. what does that mean? it's my term but it's what you do when you yelp! you hit up yelp, you find out what people say, you read the ads, and then you go spend money at that advertiser. with huge retention, the site is a winner for both advertisers and for yelp itself. it's introducing a nearby function for people to access where you can tap in on what you know people like about certain things. only a handful of companies have offerings that address all

three, the foremost is salesforce.com, a yelp partner. it started in 2004 with two employees and an office in san francisco to sell services to small and medium sized businesses just to that city, then rolled out to chicago, went national, went international. it was a very considered rollout, five new cities, then seven but now they're in 19 cities and it's 30 million to date. the reviewers create the content, not yelp, and advertisers pay yelp to follow up on the leads. yelp is winning in several ways. as more and more viewers come on, it becomes incredibly important for the company being reviewed to have a presence on yelp. and buying advertising on yelp is an easy process. and it improves on the yellow pages.

yelp has morphed into the mobile hooked it yellow pages, kind of the poster boy for the activity. think of it, can you imagine carrying around the old yellow pages? you would get a darn hernia. the advertiser stands to win big here. you're mining the traffic that you already know is interested in coming to your company at that moment. it's a remarkably powerful and robust concept. if you get new business formation, yelp should be able to leverage its model to huge success and profitability down the road. it's still losing money, penny per share a quarter, though much less than the 4 cents loss that the analysts suspected. it's got a partnership with apple that's working well. apple needs a better social and mobile strategy. it would cost apple a pittance to buy yelp and it would be the platform apple needs to protect its flank from facebook and google.

it simply must be bought by a company that needs this yellow pages of the future, and apple makes the most sense to do so. there are two ways to win here, people. there's the oxygenated growth, and then there's the takeover. that's the yelp story after this remarkably robust quarter. i want to go to juan in florida, please. juan. >> caller: booyah, jim. >> booyah, juan. >> wanted to ask you about oracle, orcl. their fourth quarter they disappointed us citing macroeconomic forces. but now that other companies it like ibm have cited similar issues with macroeconomic forces, do you believe it's time to get back into oracle? >> i like their new partner salesforce.com more than i like oracle. sometimes i wonder aloud why did oracle not make their quarters? it puzzles me because i thought they should have made them given how robust their business is

supposed to be. let's go to varun in michigan. >> caller: shouldn't apple acquire nuance, company to bring in voice tech? >> i don't think they need to. they got everything they need from nuance. searching for profits right in your neighborhood? yelp is winning. hyper growth, possible takeover and now you know what it means to yelp! stay with cramer. tomorrow kick off the trading day with "squawk on the street," live at post nine at the nyse. >> they're the best operators there is. people are slamming them. will you give me a break? give me a break! [ male announcer ] i've seen incredible things.

otherworldly things. but there are some things i've never seen before. this ge jet engine can understand 5,000 data samples per second. which is good for business. because planes use less fuel, spend less time on the ground and more time in the air. suddenly, faraway places don't seem so...far away. ♪ folks have suffered from frequent heartburn. but getting heartburn and then treating day after day is a thing of the past. block the acid with prilosec otc, and don't get heartburn in the first place. [ male announcer ] one pill each morning. 24 hours. zero heartburn.

 [ male announcer ] one pill each morning. time to have new experiences with a familiar keyboard. to update our status without opening an app. to have all our messages in one place. to browse... and share... faster than ever. ♪ it's time to do everything better than before. the new blackberry q10. it's time.

it is time for the lightning round! rapid fire calls.

play to this sound and then the lightning round is over. are you ready skeedaddy? i'm going to start with david in wisconsin. david! dave! >> caller: yeah! >> hit me! >> caller: hey, jim. dqp. would you classify that as a forever stock? >> i said on twitter @jimcramer that the important thing is they report tomorrow but it is a concept meaning don't play it for the quitter you either believe in it long term or you don't. warren in north carolina. warren! >> caller: booyah from wilmington, north carolina! >> they made a bond movie there. >> caller: they did. we are the hollywood of the east. >> you are, man. you are the beast of the east! what's up?

>> caller: i'm calling about dexcom. >> oh, the diabetes play. i was looking at the chart this weekend. it's one of the good ones. that's a plus. jared in arizona. >> caller: how are you? a big booyah from scottsdale, arizona. my dad and i love your show. >> yes! >> caller: i want to thank you for everything. a couple weeks ago, himx dropped popped about 50%. what do you think about these guys? is it a buy or a sell? >> it's a buy. if google is using their technology, i'm not going to go against these guys. google is one of the four or five smartest companies on earth. i'm thumbs up on this. i need to go to nancy in new mexico. nancy. >> caller: booyah oh great wizard of wall street. >> wow, thank you. >> caller: first i wanted to say

thank you for everything you do. i had the pleasure of speaking you back in may regarding erickson air crane and wanted to let you know all went well. my question is regarding pier one imports, it has no short-term debt no, $9 million in long-term debt, is this shackled to the home builder? >> it is still good. it is shackled to the home builders, but the home builders are going to be a great fourth quarter story and this one is really well run. we like the guy who runs it. he's always welcome on the show. tom in michigan. >> caller: hey, jim. booyah. >> booyah, tom. >> caller: what do you think of celldex? >> the stock has just completely soared here. so take a schnitzel. let the rest run. go ahead, morgan.

>> caller: my question is about sun power. i had a bullish call on it and it didn't go so well. what do you think is going on with this stock? >> no, you don't want to touch sunpower. i was willing to go with first solar because they did have a great conference call and great quarter. that's the only one i'm recommending in that group. if you want a pseudoplay, go for applied materials, they own a small sliver of that market. let's go to lois in florida. lois! >> caller: booyah, jim. we wanted to know is now the time to buy into chart industries? >> the stock is up like 16 straight points since they reported. if we don't wait for a pullback, i have to say if you haven't bought it yet, i am going to say it right here, i think it's too late and it's got to come down. and that, ladies and gentlemen, is the conclusion of the lightning round! >> the lightning round is sponsored by td ameritrade.

rise- your house was built on an ancient burial ground. [ ghosts moaning ] surprise -- your car needs a new transmission. [ coyote howls ] how about no more surprises? now you can get all the online trading tools you need without any surprise fees. ♪ it's not rocket science. it's just common sense. from td ameritrade.

these are sandra's "homemade" yummy, scrumptious bars. hmm? i just wanted you to eat more fiber. chewy, oatie, gooeyness... and fraudulence. i'm in deep, babe. you certainly are. [ male announcer ] fiber one. ♪ the world is changing faster than ever, creating new opportunities for those who stand ready to seize them. in a time when the biggest risk is playing it safe, we believe outshining the competition tomorrow requires challenging your business inside and out today. at cognizant, our flexible, collaborative approach helps forward-looking companies not only run better, but run different... to give your customers every reason to keep looking for you.

so if you're ready to see opportunities and see them through, we say: let's get to work. because now more than ever, the future belongs to those who challenge the present.

never try to bet against the hottest, most powerful tech trend out there, particularly today. never bet against the cloud, especially when it's integrated with social offerings. case in point, marketo, a fresh software as a service ipo, came public in may. they help clients streamline marketing decisions and build long-term relationships with their customers, including social media. the stock did get slammed in may with the rest of the market. fast forward to this past tuesday. marketo reports after the close and blows away the numbers. revenues up 62% on the year. 62%! this has now given you a terrific 45% gain since we

interviewed the ceo back on june 10th, less than two months ago. let's check back in with mr. phil fernandez. mr. fernandez, welcome back to "mad money." yelp, zillow, trulia, facebook. where is marketo in this? >> we're creating a new software category before everybody's eyes. there are skeptics and we're going to show them it's real. >> you have the university of miami as a customer. >> we're having this run in higher education, both student recruitment and development, and

it's one more example of the different industries finding their way to what we're doing, from brands, business software -- >> are they trying to reach out to certain students? are they doing e-mail campaign, twitter, facebook? a lot of people watch us -- have recently been students and they're trying to figure out where you are in that food chain. >> yes, yes and yes. if you're competing for students or customers in any industry, you're using us across all those channels. >> same thing with curves? >> same thing with curves, same thing with microsoft. >> you've become quite agnostic, working with salesforce and microsoft but i didn't get the sense you're working with oracle. >> they've become one of our competitors. there is something there. >> a lot of analysts questioned whether you'd be able to maintain, keep the relationships because you had a good relationship with salesforce.com. the people who were normally

using you to exact target. but according to your quarter, that hasn't happened. >> it hasn't happened. so far we've just been thriving in the light of that. >> do we know whether anyone substantive that's important to you has said we'd love to use you guys, salesforce.com, but we're going to have to leave you? >> i can't name one that's done that. >> this seems like a tipping point of major advertisers going social, mobile, going web, versus tv versus print. what happened to make it so it seems to flip so big? >> well, i think particularly as the social media properties have started to really show advertising success and show they know how to monetize, you see a virtuous cycle of

success begetting success. >> one of the things you talked about, the so-called b to c, but you've got this business to business. i'd like to use the example of lazar, an outfit, lazar asset management. who are they trying to connect to when they hire you? >> their capital markets people are trying to build relationships with buy side investors, send their news letters out and build their brand identity because they're competing with goldman sachs or anybody else for mind share, using marketing technology to find new customers. >> you talk about how plain old fashioned e-mail may no longer be the way. is that internet one now, e-mail, and there's a lot more exciting ways to do things? >> you only have to move your finger quarter inch on an iphone and you're going from social media to other things.

the customer notices that. so e-mail while it's fine is just one sliver of this world that is social, mobile and everything going on at once. >> to me microsoft is sorely wanting in this area. they're partnered with you. microsoft calls you and says listen, marketo, salesforce we're mortal enemies with, we want to buy marketo. is it too early to sell? >> we're at the earliest, earliest days of a market and there's a very big company to be built here. i'm sure everybody's looking at it. we'll do the right thing for shareholders but we hope to build a very big company. >> a lot of companies that come public, in the second quarter they do a gigantic equity offer. should our viewers be aware that anything can happen along those lines? that there might be a big equity offering? >> we're not planning anything like that.

>> you don't need cash of $100 million -- >> we're good. we're not planning any big equity offerings. >> you have a lot of momentum and i've been recommending you since you came public. >> that's a good plan. >> it is a brave new world out there and only a couple companies have figured it out. the ones that have, they're like marketo, going higher.

we've got a raging bull market in biotech right now. strongest i've ever seen. not just big boys. also some of the smaller more speculative players seem to be getting taken over left and right. tonight i want to circle back to another cramer fave biotech spec, that's acorda therapeutics. its big drug is ampyra, which helps multiple sclerosis patients regain some ability to walk. also being tested for stroke and cerebral palsy. a speculative drug like this is more about the pipeline than the earnings. just last june dramatically outperformed the s&p 500, up 18% since we interviewed them back in mid april.

let's take a closer look with dr. ron cohen to find out more about the quarter. welcome back to "mad money." >> thanks very much. >> i do call it speculative. i'm always concerned you've got a lot in the pipe that hasn't been approved, including things that are really still early on. we know ampyra is being used right now for m.s. strokes, cerebral palsy, those could be huge indications but i don't want people to think it's going to happen in the next few month. >> what's most encouraging is we've done some clinical studies in human beings with post-stroke impairment and with cerebral palsy, and we saw improvement in walking, which is a huge issue for people post-stroke and we're currently selling it for people with m.s. to improve walking. we have designed the next clinical study for people in post-stroke, we're going to talk

to the fda about it, get an agreement, and hopefully by the second quarter of '14, we'll start that clinical trial. if that goes good, we'll be on our way hopefully to getting it to people with strokes. >> people are probably wondering right now, stroke victims or their loved ones, i want to be in the test, i want to be in the test, why can't we do it in october? what takes so long? what happens between now and the second quarter? >> for us between now we have a new formulation of the drug that we think will have some advantages for patients, so we're going to finish that formulation. we also need to talk to the fda so we're talking about a matter of a few months but in exchange we'll have a new formulation that we hope will be even better for patients. >> we've been watching some of the evolution of the m.s. drugs, the biogen drugs.

some of these formulations are some of the reasons that ampyra is taking off. >> it's important to understand that ampyra is unique. it is not like all the other ms drugs. those are called disease modifying drugs. they're very important drugs, but you can potentially take ampyra together with one of those drugs. >> how many people are doing that? what's the percentage of people taking ampyra versus who could take it? >> over 80,000 people with m.s. have already tried the drug since we launched it. we think there are another 120,000 or so who have walking impairment who haven't tried it and who ought to give it a try. >> is that because doctors don't know about it, or they're afraid >> the doctors almost 100% know about it. we have a very good

understanding among the doctors. it's really among the patients and their care givers. there are so many new drugs coming for ms that it takes time to sort through what is this one for, what is that one for? we're seeing gains in awareness. >> let's talk about the neuropathic pain assets acquisition and what that means for you. it seems much smaller. not a lot of money involved but it's a big market. >> neuropathic pain is basically pain that's in your nerves and they're shooting this horrible burning pain into your brain and you can feel it, even though you don't see it. people with diabetes get it a lot, people who have chemotherapy for cancer get it a lot. the product we brought in is a patch. >> is it like this? this is capsaicin. >> the patch is a much stronger concentration.

it lasts three months. >> why wouldn't anyone who has pain want this? why is it limited to the nerve? >> when you develop therapy, you have to do clinical trials for a particular thing. you go to the fda and say we have proof for this particular thing. >> i have this because i use this. it's not as effective as i would like. if there was something that really did blunt the pain that was not addictive, it would be one of the biggest sellers in the world. >> and we would have to do those clinical trials for that kind of pain. we're interested in looking particularly next at diabetic pain. people with diabetes get this kind of pain a lot and if it could help them, that's huge. >> these are big markets, post-stroke, this, almost as big if not bigger than as m.s. >> we estimate there are as many as three million people who have had stroke and have walking problems. >> this stock remains to me one of the best you should be looking at. this is dr. ron cohen, president

and ceo of acorda therapeutics, delivering on the numbers and still a little room before it gets to its 52-week high again. stay with cramer. engineer: rolling...take 13. geico's defensive driver, good student and multi-policy discounts could save you hundreds of dollus. engineer: uh geico's discounts could save you hundreds of "doll-ars." it sounds like you're saying "dollus." dollus. engineeif you could accentuate the "r" sound of "dollars." are...are... are... engineer: are... arrrrrr. arrrrr. someone bring me an eye patch, i feel like a bloomin' pirate. geico. fifteen minutes could save you fifteen percent or more on car insurance. honestly, i feel like i nailed that.

so... [ gasps ] these are sandra's "homemade" yummy, scrumptious bars. hmm? i just wanted you to eat more fiber. chewy, oatie, gooeyness... and fraudulence. i'm in deep, babe. you certainly are. [ male announcer ] fiber one. a talking car. but i'll tell you what impresses me. a talking train. this ge locomotive can tell you exactly where it is,

what it's carrying, while using less fuel. delivering whatever the world needs, when it needs it. ♪ after all, what's the point of talking if you don't have something important to say? ♪ this market is so red hot that it does make me pause but i

got to tell you something, when you see the kinds of quarters that we saw today, shoot the lights out when you get a great number from china, great number from europe and america, the back drop is so compelling. there's always a bull market somewhere. i'm jim cramer and i will see you tomorrow! america's criminal corporation. >> money, power, status, and influence. what fuels the mafia is, i think, what fuels almost any business. >> the american mafia has been going strong for more than 80 years. >> it's pure criminal capitalism at its best. >> they specialize in loan-sharking, extortion, embezzlement, and more. >> the ability to kill gives them a special power. >> murder is a negotiating tool of last resort. >> we just don't kill people for nothing. there's rules, and you got to follow the rules. this is why they call it the mafia.